ID   RPMI-7932
AC   CVCL_2713
SY   RPMI 7932; RPMI7932; Roswell Park Memorial Institute 7932; ULF
DR   BTO; BTO:0004062
DR   CLO; CLO_0008872
DR   CLDB; cl4180
DR   CLDB; cl4181
DR   cancercelllines; CVCL_2713
DR   Cell_Model_Passport; SIDM00916
DR   Cosmic; 889039
DR   Cosmic; 928744
DR   ECACC; 94072246
DR   GEO; GSM226865
DR   ICLC; HTL96012
DR   Progenetix; CVCL_2713
DR   Wikidata; Q54951231
RX   DOI=10.1093/jnci/59.2.301;
RX   PubMed=72600;
RX   PubMed=77569;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=3180053;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=6277475;
RX   PubMed=9354451;
RX   PubMed=15048078;
RX   PubMed=17363583;
RX   PubMed=22383533;
CC   Population: Caucasian.
CC   HLA typing: A*02,03; B*07,w40 (PubMed=77569).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583).
CC   Omics: CNV analysis.
CC   Omics: SNP array analysis.
CC   Caution: The exact relationship between HMCB (Cellosaurus=CVCL_3317) and RPMI-7262/7272/7932/7962/7972 is not clear: all are derived from patient 'Bowes' melanoma.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_3317 ! HMCB
OI   CVCL_T313 ! RPMI-7262
OI   CVCL_T314 ! RPMI-7272
OI   CVCL_T315 ! RPMI-7551
OI   CVCL_T316 ! RPMI-7781
OI   CVCL_T317 ! RPMI-7801
OI   CVCL_T318 ! RPMI-7922
OI   CVCL_T319 ! RPMI-7962
OI   CVCL_T320 ! RPMI-7972
OI   CVCL_T321 ! RPMI-8002
OI   CVCL_T322 ! RPMI-8072
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 23
//
RX   DOI=10.1093/jnci/59.2.301;
RA   Quinn L.A., Woods L.K., Merrick S.B., Arabasz N.M., Moore G.E.;
RT   "Cytogenetic analysis of twelve human malignant melanoma cell lines.";
RL   J. Natl. Cancer Inst. 59:301-307(1977).
//
RX   PubMed=72600;
RA   Sharma B.;
RT   "In vitro immunization against human tumor cells with tumor cell
RT   fractions.";
RL   Cancer Res. 37:4660-4668(1977).
//
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=3180053;
RA   Lemontt J.F., Azzaria M., Gros P.;
RT   "Increased mdr gene expression and decreased drug accumulation in
RT   multidrug-resistant human melanoma cells.";
RL   Cancer Res. 48:6348-6353(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6277475;
RA   Frampton R.J., Suva L.J., Eisman J.A., Findlay D.M., Moore G.E.,
RA   Moseley J.M., Martin T.J.;
RT   "Presence of 1,25-dihydroxyvitamin D3 receptors in established human
RT   cancer cell lines in culture.";
RL   Cancer Res. 42:1116-1119(1982).
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152;
RA   Stark M.S., Hayward N.K.;
RT   "Genome-wide loss of heterozygosity and copy number analysis in
RT   melanoma using high-density single-nucleotide polymorphism arrays.";
RL   Cancer Res. 67:2632-2642(2007).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//